p-tau217 – Medxy AI

Precision Screening for Preclinical Alzheimer Disease: The Ascendance of Plasma p-tau217 as a Scalable Biomarker

By MedXY 01/02/2026

This review synthesizes recent high-impact evidence on plasma p-tau217, demonstrating its superior utility in identifying amyloid pathology, predicting cognitive decline, and optimizing recruitment for primary prevention trials in cognitively unimpaired individuals.

Neurology news

Plasma p-tau217 and GFAP Emerge as Robust Predictors of Alzheimer’s Progression in Down Syndrome

By MedXY 12/23/2025

A pivotal longitudinal study demonstrates that plasma p-tau217 and GFAP accurately predict amyloid-β and tau deposition, cognitive decline, and dementia risk in adults with Down syndrome, offering a transformative, non-invasive tool for clinical monitoring and therapeutic trials.

Cardiology Neurology news Specialties

Obicetrapib’s Role in Modulating Alzheimer’s Disease Biomarkers in Patients with Cardiovascular Disease: A Landmark Clinical Study

By MedXY 10/21/2025

Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.

Neurology news

Pregnancy Hypertension and Elevated p-tau217: A Midlife Indicator of Alzheimer’s Disease Risk in Women

By MedXY 10/21/2025

Pregnancy hypertension is independently associated with higher serum p-tau217 levels in midlife women, suggesting a link to preclinical Alzheimer’s disease pathology and potential for early screening and intervention.